Cargando…

Venetoclax + hypomethylating agents combined with dose-adjusted HAG for relapsed/refractory acute myeloid leukemia: Two case reports

RATIONALE: Some acute myeloid leukemia (AML) patients are unresponsive to treatment or have remission followed by worsening of disease (known as relapsed/refractory AML [R/RAML]) after standardized treatment. The CAG/HAG regimen is not often used clinically because heterogenous patient responses, re...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wang, Hongxia, Bai, Junjun, Pei, Zhixin, Zhang, Bei, Wang, Junjie, Lian, Xingli, Song, Qinglin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2020
Materias:	4800
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7676608/ https://www.ncbi.nlm.nih.gov/pubmed/33217852 http://dx.doi.org/10.1097/MD.0000000000023265

Ejemplares similares

Relapsed/refractory acute promyelocytic leukemia with RARA-LBD region mutation was salvaged by venetoclax: A case report
por: Li, Youli, et al.
Publicado: (2021)

Double remission of chronic lymphocytic leukemia and secondary acute myeloid leukemia after venetoclax monotherapy: A case report
por: Wang, Lei, et al.
Publicado: (2021)

Cladribine, cytarabine, and filgrastim based regimen in relapsed or refractory acute myeloid leukemia: A systematic review and meta-analysis
por: Cao, Susu, et al.
Publicado: (2023)

The prevalence, risk factors, and prognostic value of anxiety and depression in refractory or relapsed acute myeloid leukemia patients of North China
por: Gu, Mianmian, et al.
Publicado: (2019)

Outcomes of relapsed or refractory acute myeloid leukemia after front-line hypomethylating agent and venetoclax regimens
por: Maiti, Abhishek, et al.
Publicado: (2020)

Efficacy and safety of daratumumab in the treatment of relapsed/refractory multiple myeloma: A meta-analysis of randomized controlled trials
por: Huang, Zeng-Yi, et al.
Publicado: (2023)

Venetoclax combination therapy with hypomethylating agents in young adults with relapsed/refractory acute myeloid leukaemia
por: Báez-Gutiérrez, Nerea, et al.
Publicado: (2021)

Combination of DNA-hypomethylating agent and hematopoietic stem cell transplantation in treatment of juvenile myelomonocytic leukemia: A case report
por: Ai, Yuan, et al.
Publicado: (2020)

Outcomes of Adults With Relapsed/Refractory Acute Myeloid Leukemia Treated With Venetoclax Plus Hypomethylating Agents at a Comprehensive Cancer Center
por: Tenold, Matthew E., et al.
Publicado: (2021)

Long-term follow-up after rituximab plus bendamustine in a patient with relapsed or refractory hairy cell leukemia variant: A case report
por: Imoto, Naoto, et al.
Publicado: (2021)

Resistance to venetoclax and hypomethylating agents in acute myeloid leukemia
por: Saliba, Antoine N., et al.
Publicado: (2021)

Venetoclax with Decitabine or Azacitidine in Relapsed or Refractory Acute Myeloid Leukemia
por: Bouligny, Ian M., et al.
Publicado: (2023)

Intermediate dose cytarabine improves survival and relapse-free rate compared with standard-dose cytarabine as post-remission treatment for acute myeloid leukemia: A retrospection study
por: Ye, Li, et al.
Publicado: (2021)

A Successful Bridge Therapy Combining Hypomethylating Agents with Venetoclax for Adult Patients with Newly Diagnosed or Relapsed/Refractory Acute Myeloid Leukemia
por: Bang, Su-Yeon, et al.
Publicado: (2023)

P577: EFFICACY OF SELINEXOR COMBINED WITH A HYPOMETHYLATING AGENT IN THE TREATMENT OF REFRACTORY/RELAPSED ACUTE MYELOID LEUKEMIA IN PATIENTS EXPOSED TO VENETOCLAX
por: Zhang, Jian, et al.
Publicado: (2023)

Chylothorax after chimeric antigen receptor T cell therapy for relapsed and refractory diffuse large B-cell lymphoma: A case report
por: Chen, Hsin-Hui, et al.
Publicado: (2023)

Age-Adjusted Schedules of Venetoclax and Hypomethylating Agents to Treat Extremely Elderly Patients with Acute Myeloid Leukemia
por: Lee, Aaron M., et al.
Publicado: (2022)

Busulfan and Fludarabine Conditioning Regimen Given at Hematological Nadir of Cytoreduction Fludarabine, Cytarabine, and Idarubicin Chemotherapy in Patients With Refractory Acute Myeloid Leukemia Undergoing Allogeneic Stem Cell Transplantation: A Single Arm Pilot Consort Study
por: Tang, Wei, et al.
Publicado: (2015)

Safety and Efficacy: Clinical Experience of Venetoclax in Combination With Hypomethylating Agents in Both Newly Diagnosed and Relapsed/Refractory Advanced Myeloid Malignancies
por: Feld, Jonathan, et al.
Publicado: (2021)

Anxiety and depression predict unfavorable survival in acute myeloid leukemia patients
por: Ding, Ting, et al.
Publicado: (2019)

Gemtuzumab ozogamicin monotherapy prior to stem cell infusion induces sustained remission in a relapsed acute myeloid leukemia patient after allogeneic stem cell transplantation: A case report
por: Sumiyoshi, Ritsu, et al.
Publicado: (2020)

Pulmonary hypertension in patients with chronic myeloid leukemia
por: Song, Ik-Chan, et al.
Publicado: (2021)

Venetoclax as monotherapy and in combination with hypomethylating agents or low dose cytarabine in relapsed and treatment refractory acute myeloid leukemia: a systematic review and meta-analysis
por: Bewersdorf, Jan Philipp, et al.
Publicado: (2020)

Venetoclax in Relapsed/Refractory Acute Myeloid Leukemia: Are Supporting Evidences Enough?
por: Brancati, Serena, et al.
Publicado: (2021)

Role of autoimmune hemolytic anemia as an initial indicator for chronic myeloid leukemia: A case report
por: Li, Xiang, et al.
Publicado: (2020)

Transformation from acute promyelocytic leukemia to acute myeloid leukemia with a CEBPA double mutation: A case report and review of the literature
por: Sun, Ye, et al.
Publicado: (2021)

Polyserositis as a primary clinical manifestation of CD7+ acute myelogenous leukemia with myeloid sarcoma: A case report
por: Pi, Yubo, et al.
Publicado: (2020)

Acute myeloid leukemia presenting as erythema nodosum: A case report
por: Xu, Xiaohan, et al.
Publicado: (2017)

DNMT3A mutations in Chinese childhood acute myeloid leukemia
por: Li, Weijing, et al.
Publicado: (2017)

The transformation of isolated gastric myeloid sarcoma into acute myeloid leukemia presenting with a complex karyotype and TLS-ERG gene fusion: A case report
por: Gao, Lu, et al.
Publicado: (2022)

Chimeric antigen receptor-modified T-cell therapy for bone marrow and skin relapse Philadelphia chromosome-like acute lymphoblastic leukemia: A case report
por: Yang, Mianzeng, et al.
Publicado: (2020)

The prognostic value of the peripheral blood cell counts changes during induction chemotherapy in Chinese patients with adult acute myeloid leukemia
por: Huang, Yuan-Mao, et al.
Publicado: (2021)

Dasatinib associated lymphadenopathy in a chronic myeloid leukemia patient: A case report
por: Pilalas, Dimitrios, et al.
Publicado: (2020)

Identification of the hub genes and pathways involved in acute myeloid leukemia using bioinformatics analysis
por: Tan, Youping, et al.
Publicado: (2020)

Variables associated with patient-reported symptoms in persons with chronic phase chronic myeloid leukemia receiving tyrosine kinase inhibitor therapy
por: Yu, Lu, et al.
Publicado: (2019)

Retrospective Comparison of Fludarabine in Combination With Intermediate-Dose Cytarabine Versus High-Dose Cytarabine As Consolidation Therapies for Acute Myeloid Leukemia
por: Zhang, Wenjun, et al.
Publicado: (2014)

Genetic polymorphisms of NAT2 and risk of acute myeloid leukemia: A case-control study
por: Zou, Yunding, et al.
Publicado: (2017)

P507: SALVAGE THERAPY WITH VENETOCLAX IN COMBINATION WITH AZACITIDINE, HOMOHARRINGTONINE AND CYTARABINE IN PATIENTS WITH RELAPSED/REFRACTORY ACUTE MYELOID LEUKEMIA
por: Yuan, Linyu, et al.
Publicado: (2023)

The efficacy and safety of daunorubicin versus idarubicin combined with cytarabine for induction therapy in acute myeloid leukemia: A meta-analysis of randomized clinical trials
por: Wang, Hanyu, et al.
Publicado: (2020)

Venetoclax Plus Gilteritinib for FLT3-Mutated Relapsed/Refractory Acute Myeloid Leukemia
por: Daver, Naval, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_7kultcvmv1hprphccrvdncc82i